23:35:57 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-29 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-29 Ordinarie utdelning POLAR 0.00 SEK
2024-05-28 Årsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-11-24 Kvartalsrapport 2023-Q3
2023-09-08 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-17 Årsstämma 2023
2023-05-05 Ordinarie utdelning POLAR 0.00 SEK
2023-03-13 Extra Bolagsstämma 2022
2023-02-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-05-06 Ordinarie utdelning POLAR 0.00 SEK
2022-05-05 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning POLAR 0.00 SEK
2021-05-05 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning POLAR 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2020-02-14 Extra Bolagsstämma 2020
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-24 Kvartalsrapport 2019-Q2
2019-05-07 Split POLAR 16:1
2019-04-26 Kvartalsrapport 2019-Q1
2019-03-19 Årsstämma 2019
2019-02-04 Ordinarie utdelning POLAR 0.00 SEK
2019-02-01 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Polarcool är verksamt inom medicinteknik. Idag är bolaget inriktade mot att produkter och lösningar inriktade för skador inom sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador vid exempelvis boxning, rugby och amerikansk fotboll. Verksamhet innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2021-10-21 15:11:00

Biarritz Olympique Pays Basque, a Top14 team in French rugby league, signs an agreement with PolarCool AB (publ) to use the PolarCap® System. The agreement means that the Pays Basques club will use the PolarCap® System for an initial six-week period with the aim to subsequently sign a commercial agreement.

PolarCool has established a contact with Matthew Clarkin, Biarritz Olympique Pays Basque's Director of Sports.  He has evaluated the scientific background and the clinical evidence of PolarCap® System.

Biarritz Olympique Pays Basque's Director of Sports Matthew Clarkin comments:

- Players' safety is important to us at Biarritz Olympique Pays Basque. The fact that there is now also robust scientific evidence for PolarCap® System makes us confident that we now can offer improved medical treatment for our players suffering concussions.

On the 28[th] of September PolarCool AB announced a break-through on the French market within rugby, when the company signed an evaluation agreement with the French professional rugby club Stade Français. In the agreement Stade Français also agreed to introduce PolarCap® System to other clubs in the French first league. As a result, Biarritz Olympique Pays Basque becomes the next Top 14 Club to sign an agreement with the aim to subsequently sign a commercial agreement.

PolarCool's CEO Erik Andersson comments:

- It's evident that our marketing strategy breakthrough in French rugby has made an impact. It has now resulted in another Top 14 team in the league ready to use the PolarCap® System as a treatment for concussions. The marketing prospects look promising in France, and we are excited to continue to establish PolarCap® as a treatment for rugby players suffering concussions, not only in France but in the world of rugby.